Cellular Immunotolerance in the Transplant

  • Marcos Lóez-HoyosEmail author
  • David San Segundo
  • Manuel Arias
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 741)


In humans, a state of operational tolerance has been observed in some recipients who anecdotally or experimentally abandoned their immunosuppressive treatment. Besides, advances in the understanding of the immune response and the continuous appearance of new biological molecules have boosted the growing interest in transferring the knowledge concerning immune tolerance from experimental models to clinical transplantation. Most of the strategies for inducing tolerance target the T-lymphocytes, especially T CD4+ since they play a central role in the regulation of the immune response. However, an effective tolerogenic treatment must also take into account the role of alloantibody producing B-lymphocytes, which have been shown to play a fundamental role in chronic rejection phenomena. There are multiple regulation and silencing mechanisms that operate both during lymphocyte ontogeny in the bone marrow and thymus (central tolerance) and in the periphery (peripheral tolerance). These regulatory mechanisms include the destruction of APCs by cytotoxic lymphocytes, suppressive cytokines, and activation-induced cell death, among others. However, the mechanism that in recent years has come to be attributed the greatest role has been the active suppression of the response by T-lymphocytes themselves. These lymphocytes are named as regulatory T cells that include Tregs CD4+CD25+, Tr1 cells and Th3. The great therapeutic potential of regulatory lymphocyte populations for the control of allogeneic rejection is evident and several clinical trials in humans have been started to be implemented using populations of both Tregs and Tr1 cells for the prevention of allogeneic reactions.


Treg Cell Secondary Lymphoid Organ Peripheral Tolerance Costimulatory Signal Central Tolerance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sykes M. Immune tolerance: mechanisms and application in clinical transplantation. J Intern Med 2007; 262:288–310.PubMedCrossRefGoogle Scholar
  2. 2.
    Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 1:97–102.PubMedCrossRefGoogle Scholar
  3. 3.
    Biederman BC, Pober JS. Human endothelial cells induce and regulate cytolytic T-cell differentiation. J Immunol 1998; 161:4679–4687.Google Scholar
  4. 4.
    Lin T, Zhou W, Sacks SH. The role of complement and Toll-like receptor in organ transplantation. Transplant Int 2007; 20:481–489.CrossRefGoogle Scholar
  5. 5.
    Jukes JP, Wood KJ, Jones ND. Natural killer T-cells: a bridge to tolerance or a pathway to rejection? Transplantation 2007; 84:679–681.PubMedCrossRefGoogle Scholar
  6. 6.
    Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol 2007; 7:942–953.PubMedCrossRefGoogle Scholar
  7. 7.
    Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003; 3:794–803.PubMedCrossRefGoogle Scholar
  8. 8.
    Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515–548.PubMedCrossRefGoogle Scholar
  9. 9.
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715–2729.PubMedCrossRefGoogle Scholar
  10. 10.
    Mueller TF, Einecke G, Reeve J et al. Microarrays analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7:2712–2722.PubMedCrossRefGoogle Scholar
  11. 11.
    Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3:665–673.PubMedCrossRefGoogle Scholar
  12. 12.
    Stasikowska O, Wagrowska-Danilewicz M. Chemokines and chemokine receptors in glomerulonephritis and renal allograft rejection. Med Sci Monit 2007; 13:RA31–RA36.PubMedGoogle Scholar
  13. 13.
    Weaver CT, Hatton RD, Mangan PR et al. IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu Rev Immunol 2007; 25:821–852.PubMedCrossRefGoogle Scholar
  14. 14.
    Chen Y, Wood KJ. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? Transplantation 2007; 84:1071–1074.PubMedCrossRefGoogle Scholar
  15. 15.
    Newell KA, Larsen CP, Kirk AD. Transplant tolerance: converging on a moving target. Transplantation 2006; 81:1–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Ashton-Chess J, Giral M, Brouard S et al. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal transplantation. 2007; 84:1215–1219.Google Scholar
  17. 17.
    Anderson G, Lane PJ, Jenkinson EJ. Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol 2007; 7:954–963.PubMedCrossRefGoogle Scholar
  18. 18.
    St. Clair EW, Turka LA, Saxon A et al. New reagents on the horizon for immune tolerance. Ann Rev Med 2007; 58:1–18.CrossRefGoogle Scholar
  19. 19.
    Lakkis FG, Sayegh MH. Memory T-cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14:2402–2410.PubMedCrossRefGoogle Scholar
  20. 20.
    Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610–621.PubMedCrossRefGoogle Scholar
  21. 21.
    Akl A, Luo S, Wood KJ. Induction of transplantation tolerance-the potential of regulatory T-cells. Transplant Immunol 2005; 14:225–230.CrossRefGoogle Scholar
  22. 22.
    Sakaguchi S, Sakaguchi N, Asano M et al. Immunologic self-tolerance maintained by activated T-cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151–1164.PubMedGoogle Scholar
  23. 23.
    Wood KJ, Sakaguchi S. Regulatory T-cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199–210.PubMedCrossRefGoogle Scholar
  24. 24.
    Roncarolo M.G, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7:585–597.PubMedCrossRefGoogle Scholar
  25. 25.
    Banham AH. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T-cells. Trend Immunol 2006; 27:541–544.CrossRefGoogle Scholar
  26. 26.
    LeBlanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262:509–525.CrossRefGoogle Scholar
  27. 27.
    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell response. Blood 2005; 105:1815–1822.PubMedCrossRefGoogle Scholar
  28. 28.
    Popp FC, Eggenhofer E, Renner P et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in sinergy with low-dose mycophenolate. Transplant Immunol 2008; 20:55–60.CrossRefGoogle Scholar
  29. 29.
    Demirkiran A, Hendrikx TK, Baan C et al. Impact of immunosuppressive drugs on CD4+C25+FOXP3+ regulatory T-cells: does in vitro evidence translate to the clinical setting? Transplantation 2008; 85:783–789.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Marcos Lóez-Hoyos
    • 1
    Email author
  • David San Segundo
    • 2
  • Manuel Arias
    • 3
  1. 1.Immunology UnitMarqués de Valdecilla University HospitalSantander, CantabriaSpain
  2. 2.Immunology Research, Immunology Unit, IFIMAVMarqués de Valdecilla University HospitalSantander, CantabriaSpain
  3. 3.Marqués de Valdecilla University Hospital and University of CantabriaSantander, CantabriaSpain

Personalised recommendations